| [1] |
Cozzolino M, Shilov E, Li Z, et al. Pattern of laboratory parameters and management of secondary hyperparathyroidism in countries of Europe, Asia, the Middle East, and North America[J]. Adv Ther, 2020, 37(6): 2748-2762.
doi: 10.1007/s12325-020-01359-1
pmid: 32410164
|
| [2] |
Wang J, Bieber BA, Hou FF, et al. Mineral and bone disorder and management in the China dialysis outcomes and practice patterns study[J]. Chin Med J (Engl), 2019, 132(23): 2775-2782.
|
| [3] |
Pimentel A, Ureña-Torres P, Zillikens MC, et al. Fractures in patients with CKD-diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of nephrology dialysis and transplantation[J]. Kidney Int, 2017, 92(6): 1343-1355.
doi: S0085-2538(17)30567-7
pmid: 28964571
|
| [4] |
Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) guideline update: what’s changed and why it matters[J]. Kidney Int, 2017, 92(1): 26-36.
doi: S0085-2538(17)30249-1
pmid: 28646995
|
| [5] |
West SL, Lok CE, Langsetmo L, et al. Bone mineral density predicts fractures in chronic kidney disease[J]. J Bone Miner Res, 2015, 30(5): 913-919.
doi: 10.1002/jbmr.2406
URL
|
| [6] |
Leder BZ. Parathyroid hormone and parathyroid hormone-related protein analogs in osteoporosis therapy[J]. Curr Osteoporos Rep, 2017, 15(2): 110-119.
doi: 10.1007/s11914-017-0353-4
URL
|
| [7] |
Iimori S, Mori Y, Akita W, et al. Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients-a single-center cohort study[J]. Nephrol Dial Transplant, 2012, 27(1): 345-351.
doi: 10.1093/ndt/gfr317
URL
|
| [8] |
Kumar R, Thompson JR. The regulation of parathyroid hormone secretion and synthesis[J]. J Am Soc Nephrol, 2011, 22(2): 216-224.
doi: 10.1681/ASN.2010020186
URL
|
| [9] |
Wojda SJ, Donahue SW. Parathyroid hormone for bone regeneration[J]. J Orthop Res, 2018, 36(10): 2586-2594.
doi: 10.1002/jor.24075
URL
|
| [10] |
Murray TM, Rao LG, Divieti P, et al. Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl- terminal ligands[J]. Endocr Rev, 2005, 26(1): 78-113.
doi: 10.1210/er.2003-0024
URL
|
| [11] |
Malluche HH, Davenport DL, Cantor T, et al. Bone mineral density and serum biochemical predictors of bone loss in patients with CKD on dialysis[J]. Clin J Am Soc Nephrol, 2014, 9(7): 1254-1262.
doi: 10.2215/CJN.09470913
URL
|
| [12] |
Huang GS, Chu TS, Lou MF, et al. Factors associated with low bone mass in the hemodialysis patients-a cross-sectional correlation study[J]. BMC Musculoskelet Disord, 2009, 10: 60.
doi: 10.1186/1471-2474-10-60
URL
|
| [13] |
Jerome CP, Burr DB, Van Bibber T, et al. Treatment with human parathyroid hormone(1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis)[J]. Bone, 2001, 28(2): 150-159.
pmid: 11182372
|
| [14] |
Lau WL, Obi Y, Kalantar-Zadeh K. Parathyroidectomy in the management of secondary hyperparathyroidism[J]. Clin J Am Soc Nephrol, 2018, 13(6): 952-961.
|
| [15] |
郑淑蓓, 郑育, 李占园, 等. 成纤维细胞生长因子23、Klotho蛋白与血液透析患者骨密度改变的关系[J]. 中华肾脏病杂志, 2016, 32(5): 321-326.
doi: 10.3760/cma.j.issn.1001-7097.2016.05.001
|
| [16] |
Chu X, Zhu Y, Wang O, et al. Bone mineral density and its serial changes are associated with PTH levels in pseudohypoparathyroidism type 1B patients[J]. J Bone Miner Res, 2018, 33(4): 743-752.
doi: 10.1002/jbmr.3360
URL
|
| [17] |
Gao C, Qiao J, Li SS, et al. The levels of bone turnover markers 25(OH)D and PTH and their relationship with bone mineral density in postmenopausal women in a suburban district in China[J]. Osteoporos Int, 2017, 28(1): 211-218.
doi: 10.1007/s00198-016-3692-6
pmid: 27468899
|
| [18] |
Kazama JJ, Wakasugi M. Parathyroid hormone and bone in dialysis patients[J]. Ther Apher Dial, 2018, 22(3): 229-235.
doi: 10.1111/1744-9987.12678
URL
|
